Ovid Therapeutics Inc.: 10-K filed 2019-03-07

Name: Ovid Therapeutics Inc.: 10-K filed 2019-03-07
Creator: Ovid Therapeutics Inc.

What Ovid Therapeutics Inc. reported in its annual report filed 2019-03-07 (fiscal FY 2018): 32 published measures, 96 facts as tagged in accession 0001564590-19-006804.

This filing

Form: 10-K (annual report)
Filed: 2019-03-07
Fiscal period: fiscal FY 2018
Accession: 0001564590-19-006804 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Ovid Therapeutics Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2018-12-31	47,649,602	USD
At 2017-12-31	89,457,603	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2018-12-31	38,805,145	USD
At 2017-12-31	83,436,503	USD
At 2016-12-31	49,294,475	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2018-12-31	36,489,618	USD
At 2017-12-31	87,125,600	USD
At 2016-12-31	51,939,661	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2018-10-01 to 2018-12-31	-12,900,000	USD	92
2018-01-01 to 2018-12-31	-51,979,610	USD	365
2018-07-01 to 2018-09-30	-12,962,000	USD	92
2018-04-01 to 2018-06-30	-12,935,000	USD	91
2018-01-01 to 2018-03-31	-13,183,000	USD	90
2017-10-01 to 2017-12-31	-10,960,000	USD	92
2017-01-01 to 2017-12-31	-64,806,054	USD	365
2017-07-01 to 2017-09-30	-9,358,000	USD	92
2017-04-01 to 2017-06-30	-10,248,000	USD	91
2017-01-01 to 2017-03-31	-34,239,000	USD	90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2018-01-01 to 2018-12-31	-45,558,480	USD	365
2017-01-01 to 2017-12-31	-31,469,909	USD	365

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2018-01-01 to 2018-12-31	33,871	USD	365
2017-01-01 to 2017-12-31	38,907	USD	365

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2018-01-01 to 2018-12-31	286,140	USD	365
2017-01-01 to 2017-12-31	66,703,235	USD	365

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2018-01-01 to 2018-12-31	-5,363,642	USD	365
2017-01-01 to 2017-12-31	-47,387	USD	365

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2018-12-31	-152,695,278	USD
At 2017-12-31	-100,715,668	USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

Period	Value	Unit	Days
2018-01-01 to 2018-12-31	0	USD	365

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2018-12-31	69,867	USD
At 2017-12-31	51,775	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2018-01-01 to 2018-12-31	7,063,941	USD	365
2017-01-01 to 2017-12-31	6,397,756	USD	365

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2018-01-01 to 2018-12-31	-52,931,683	USD	365
2017-01-01 to 2017-12-31	-65,007,563	USD	365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2018-12-31	44,268,147	USD
At 2017-12-31	88,588,048	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2018-12-31	8,844,457	USD
At 2017-12-31	6,021,100	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2018-12-31	3,755,595	USD
At 2017-12-31	2,025,766	USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

Period	Value	Unit	Days
At 2018-12-31	391,872	USD
At 2017-12-31	124,194	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2018-10-01 to 2018-12-31	13,116,000	USD	92
2018-01-01 to 2018-12-31	52,931,683	USD	365
2018-07-01 to 2018-09-30	13,176,000	USD	92
2018-04-01 to 2018-06-30	13,210,000	USD	91
2018-01-01 to 2018-03-31	13,430,000	USD	90
2017-10-01 to 2017-12-31	11,048,000	USD	92
2017-01-01 to 2017-12-31	65,007,563	USD	365
2017-07-01 to 2017-09-30	9,409,000	USD	92
2017-04-01 to 2017-06-30	10,288,000	USD	91
2017-01-01 to 2017-03-31	34,262,000	USD	90

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2018-01-01 to 2018-12-31	33,790,031	USD	365
2017-01-01 to 2017-12-31	49,972,102	USD	365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2018-12-31	24,654,114	shares
At 2017-12-31	24,606,256	shares

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

Period	Value	Unit	Days
At 2018-12-31	-1,829	USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

Period	Value	Unit	Days
At 2018-12-31	86,164	USD
At 2017-12-31	50,915	USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

Period	Value	Unit	Days
At 2018-12-31	391,872	USD
At 2017-12-31	124,194	USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

Period	Value	Unit	Days
At 2018-12-31	5,088,862	USD
At 2017-12-31	3,995,334	USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

Period	Value	Unit	Days
At 2018-12-31	2,767,495	USD
At 2017-12-31	1,462,448	USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

Period	Value	Unit	Days
2018-01-01 to 2018-12-31	-51,981,439	USD	365
2017-01-01 to 2017-12-31	-64,806,054	USD	365

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

Period	Value	Unit	Days
2018-10-01 to 2018-12-31	-12,900,000	USD	92
2018-01-01 to 2018-12-31	-51,979,610	USD	365
2018-07-01 to 2018-09-30	-12,962,000	USD	92
2018-04-01 to 2018-06-30	-12,935,000	USD	91
2018-01-01 to 2018-03-31	-13,183,000	USD	90
2017-10-01 to 2017-12-31	-10,960,000	USD	92
2017-01-01 to 2017-12-31	-64,806,054	USD	365
2017-07-01 to 2017-09-30	-9,358,000	USD	92
2017-04-01 to 2017-06-30	-10,248,000	USD	91
2017-01-01 to 2017-03-31	-34,239,000	USD	90

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2018-01-01 to 2018-12-31	19,141,652	USD	365
2017-01-01 to 2017-12-31	15,035,461	USD	365

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

Period	Value	Unit	Days
2018-01-01 to 2018-12-31	35,249	USD	365
2017-01-01 to 2017-12-31	26,917	USD	365

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

Period	Value	Unit	Days
2018-01-01 to 2018-12-31	141,733	USD	365
2017-01-01 to 2017-12-31	80,310	USD	365

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

Period	Value	Unit	Days
2018-01-01 to 2018-12-31	106,484	USD	365
2017-01-01 to 2017-12-31	53,393	USD	365

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

Period	Value	Unit	Days
2018-10-01 to 2018-12-31	216,000	USD	92
2018-01-01 to 2018-12-31	952,073	USD	365
2018-07-01 to 2018-09-30	214,000	USD	92
2018-04-01 to 2018-06-30	275,000	USD	91
2018-01-01 to 2018-03-31	247,000	USD	90
2017-10-01 to 2017-12-31	88,000	USD	92
2017-01-01 to 2017-12-31	201,509	USD	365
2017-07-01 to 2017-09-30	51,000	USD	92
2017-04-01 to 2017-06-30	40,000	USD	91
2017-01-01 to 2017-03-31	23,000	USD	90

Inspect the source

Entity: Ovid Therapeutics Inc. / CIK 0001636651
Captured: 2026-09-21T17:21:21.098Z
SEC response SHA-256: b4de1e66c6e8e0453b1f8d4fc2f1dafe6798859207cf5a42629d88fe4c5e512a

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001636651.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))